| NCT06793332 | Fudan University | Triple-Negative Breast Cancer (TNBC)|Brain Metastases | 2024-12-17 | PHASE2 |
| NCT07017673 | Cedars-Sinai Medical Center|Summit Therapeutics | TNBC|TNBC - Triple-Negative Breast Cancer|Early Stage Triple-Negative Breast Carcinoma | 2025-07-25 | PHASE2 |
| NCT07229417 | M.D. Anderson Cancer Center | Metastatic Endocrine Refractory|Triple Negative Invasive Lobular Carcinoma | 2025-10-22 | PHASE2 |
| NCT06196697 | Harbin Medical University | Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma | 2024-04-10 | PHASE2 |
| NCT06951646 | Second Xiangya Hospital of Central South University|Nanjing Shihejiyin Technology, Inc.|Akeso | Non Small Cell Lung Cancer|Immune Checkpoint Inhibitors (ICIs) | 2026-03-10 | PHASE2 |
| NCT06529718 | UNICANCER|Cancer Research UK & UCL Cancer Trials Centre|Belgian Group of Digestive Oncology|Summit Therapeutics | Biliary Tract Cancer | 2025-10-09 | PHASE2 |
| NCT05184712 | Akeso | Non-Squamous Non-small Cell Lung Cancer | 2022-01-25 | PHASE3 |
| NCT07070479 | Ming-Yuan Chen | Recurrent or Metastatic Nasopharyngeal Carcinoma | 2025-06-24 | PHASE2 |
| NCT07228832 | Summit Therapeutics | Metastatic Colorectal Cancer (CRC) | 2025-11-18 | PHASE3 |
| NCT06959550 | M.D. Anderson Cancer Center|Akesobio Australia Pty Ltd|Summit Therapeutics | Metastatic Colorectal Cancer | 2025-07-28 | PHASE2 |
| NCT06805617 | Glenn J. Hanna|Summit Therapeutics | Salivary Gland Cancer|Advanced Salivary Gland Carcinoma|Metastatic Salivary Gland Cancer|Adenoid Cystic Carcinoma | 2025-02-26 | PHASE2 |
| NCT05582499 | Fudan University | Breast Neoplasm|Breast Cancer|Breast Tumors|Triple-Negative Breast Cancer (TNBC)|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer | 2022-11-01 | PHASE2 |
| NCT07070466 | Massachusetts General Hospital|Summit Therapeutics | Stomach Cancer Stage IV|Esophagus Cancer|Stomach Cancer | 2025-10-10 | PHASE2 |
| NCT07516925 | Memorial Sloan Kettering Cancer Center|Summit Therapeutics | Leiomyosarcoma | 2026-04-01 | PHASE2 |
| NCT06840834 | Intergroupe Francophone de Cancerologie Thoracique|Summit Therapeutics | Pleural Mesotheliomas | 2025-06-30 | PHASE2 |
| NCT06769971 | Sichuan University | Small Cell Lung Cancer | 2025-02-01 | PHASE2 |
| NCT06844422 | Shandong Cancer Hospital and Institute | Pancreatic Cancer | 2025-02-08 | PHASE1|PHASE2 |
| NCT06145308 | Peking Union Medical College|Peking University Hospital of Stomatology | Salivary Gland Carcinoma|Precision Therapy | 2023-08-15 | PHASE2 |
| NCT07162714 | Zhejiang Cancer Hospital|Akeso | Rectal Cancer|Radiation|AK112 | 2025-09-01 | PHASE2 |
| NCT06672575 | M.D. Anderson Cancer Center|Summit Therapeutics | Glioblastoma | 2025-01-30 | PHASE1|PHASE2 |
| NCT07234877 | European Organisation for Research and Treatment of Cancer - EORTC|Summit Therapeutics | Non Small Cell Lung Cancer | 2026-04 | PHASE2 |
| NCT06750952 | Sun Yat-sen University | Relapsed or Metastatic Thymic Cancer|First-line Treatment | 2024-12-20 | PHASE2 |
| NCT06940518 | M.D. Anderson Cancer Center|Strategic Alliance|Summit Therapeutics | Ivonescimab|Clear Cell Renal Carcinoma | 2025-07-02 | PHASE2 |
| NCT06928389 | Akeso | Non-Small Cell Lung Cancer | 2025-07-08 | PHASE3 |
| NCT06875076 | The First Hospital of Jilin University | Pretreated Pleural Mesothelioma | 2025-03-08 | PHASE2 |
| NCT06814067 | Fudan University|Fujian Cancer Hospital | Head and Neck Squamous Cell Carcinoma|Head and Neck Squamous Cell Carcinoma HNSCC | 2025-02-10 | PHASE2 |
| NCT06766591 | Jiangsu Province Nanjing Brain Hospital|Henan Cancer Hospital|Three Gorges Hospital of Chongqing University | NSCLC|Chemotherapy|Leptomeningeal Metastases|EGFR-TKI|AK112 | 2025-01-01 | NA |
| NCT06767514 | Summit Therapeutics | Non-Small Cell Lung Cancer | 2025-02-27 | PHASE3 |
| NCT07204548 | Sun Yat-sen University | Non Small Cell Lung Cancer (Stage III) | 2025-10 | PHASE2 |
| NCT07038915 | M.D. Anderson Cancer Center | Lung Squamous Cell Carcinoma|Anti-PD1+PDL1 Antibody | 2025-07-28 | PHASE2 |
| NCT06820762 | The Second Affiliated Hospital of Dalian Medical University|Shengjing Hospital | SCLC | 2025-02-28 | PHASE2 |
| NCT07057791 | PrECOG, LLC.|Summit Therapeutics | Extensive Stage Lung Small Cell Cancer | 2026-03-30 | PHASE2 |
| NCT07244965 | Women´s Hospital School Of Medicine Zhejiang University | LOCALLY ADVANCED CERVICAL CANCERS | 2025-12-01 | PHASE2 |
| NCT01042379 | QuantumLeap Healthcare Collaborative | Breast Neoplasms|Breast Cancer|Breast Tumors|Angiosarcoma|TNBC - Triple-Negative Breast Cancer|HER2-positive Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Tumor|Hormone Receptor Negative Tumor|Early-stage Breast Cancer|Locally Advanced Breast Cancer | 2010-03-01 | PHASE2 |
| NCT07158489 | Swiss Cancer Institute | NSCLC|NSCLC (Advanced Non-small Cell Lung Cancer) | 2026-07 | PHASE2 |
| NCT06814158 | Tianjin Medical University Cancer Institute and Hospital | Esophageal Squamour Cell Cancer | 2025-03-01 | PHASE2 |
| NCT05899608 | Summit Therapeutics | Non-Small Cell Lung Cancer | 2023-10-26 | PHASE3 |
| NCT07397338 | Revolution Medicines, Inc.|Summit Therapeutics | Advanced Solid Tumors|Metastatic Solid Tumors|Non-small Cell Lung Cancer (NSCLC)|NSCLC|Colorectal Cancer (CRC)|CRC | 2026-01-30 | PHASE1|PHASE2 |
| NCT06489197 | Tianjin Medical University Cancer Institute and Hospital | ESCC|Advanced Esophageal Squamous Cell Carcinoma | 2024-11-16 | PHASE2 |
| NCT06802666 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Locally Advanced Rectal Cancer|Neoadjuvant Therapy | 2024-10-16 | PHASE2 |
| NCT06444009 | Lei Liu | Head and Neck Squamous Cell Carcinoma | 2024-07-01 | PHASE2 |
| NCT06491472 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|Akesobio | Pancreatic Cancer | 2024-07-15 | PHASE2 |
| NCT07374250 | Sichuan University | Gastric Cancer|RCT | 2026-02-01 | PHASE2 |
| NCT06567314 | M.D. Anderson Cancer Center|Summit Therapeutics | Cutaneous Squamous Cell Carcinoma | 2024-12-02 | PHASE2 |
| NCT06980077 | Jonsson Comprehensive Cancer Center|Summit Therapeutics | Thymus Carcinoma | 2025-07-15 | PHASE2 |
| NCT07565389 | National University Hospital, Singapore | Nasopharyngeal Carcinoma (NPC) | 2026-05 | PHASE2 |
| NCT07394218 | Fudan University | Metastatic Breast Cancer ( HER2 Negative)|ctDNA | 2025-12-24 | PHASE2 |
| NCT06846346 | UNICANCER|Summit Therapeutics | Metastatic Esophageal Adenocarcinoma|Advanced Esophageal Adenocarcinoma|Metastatic Gastric Adenocarcinoma|Advanced Gastric Adenocarcinoma | 2025-11-20 | PHASE2 |
| NCT06848842 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Colorectal Liver Metastases | 2025-09-18 | PHASE2 |
| NCT07094685 | University of Michigan Rogel Cancer Center|Summit Therapeutics | Advanced Head and Neck Squamous Cell Carcinoma|Resectable Head and Neck Squamous Cell Carcinoma|Stage II Head and Neck Cutaneous Squamous Cell Carcinoma|Stage III Head and Neck Cutaneous Squamous Cell Carcinoma|Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma | 2025-11-18 | PHASE2 |
| NCT07535437 | Memorial Sloan Kettering Cancer Center|Summit Therapeutics | Non-Small Cell Lung Cancer | 2026-04-09 | PHASE1|PHASE2 |
| NCT07405190 | Massachusetts General Hospital|Summit Therapeutics | Lung Cancer (NSCLC)|Lung Cancer Non-Small Cell Cancer (NSCLC)|Lung Cancer (Non-Small Cell)|Lung Cancer - Non Small Cell|Lung Cancer Non Small Cell|Genomic Alterations | 2026-08-04 | PHASE2 |
| NCT06977542 | Fudan University | TNBC, Triple Negative Breast Cancer | 2025-06 | PHASE2 |
| NCT07264075 | Groupe Oncologie Radiotherapie Tete et Cou|Akeso Biopharma Co., Ltd.|Summit Therapeutics | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | 2026-04 | PHASE3 |
| NCT07363408 | City of Hope Medical Center|National Cancer Institute (NCI) | Advanced Microsatellite Stable Colorectal Carcinoma|Metastatic Microsatellite Stable Colorectal Carcinoma|Stage III Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8 | 2026-07-21 | PHASE1 |
| NCT06913218 | Akeso|Fudan University | Pancreas Cancer|Pancreas Cancer, Duct Cell Adenocarcinoma | 2025-07-22 | PHASE1 |
| NCT07359040 | Peking University People´s Hospital | Non-Small Cell Lung Cancer|Neoadjuvant Therapy|PD-1 Inhibitors|Immunotherapy | 2025-07-01 | |
| NCT07412262 | Guangdong Association of Clinical Trials|Innovent Biologics, Inc.|Akesobio | Non-Small Cell Lung Cancer | 2026-05-15 | PHASE2 |
| NCT06991491 | West China Hospital | Pancreatic Cancer | 2025-06-01 | PHASE2 |
| NCT07339839 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | NSCLC Stage IV|KRAS G12C | 2026-03-01 | PHASE1|PHASE2 |
| NCT06925724 | Memorial Sloan Kettering Cancer Center|Summit Therapeutics | Endometrial Cancer|Cervical Cancer | 2025-04-04 | PHASE2 |
| NCT07359456 | UNICANCER|Summit Therapeutics | Metastatic Colorectal Cancer | 2026-03 | PHASE2 |
| NCT06868732 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 2025-04-02 | PHASE1 |
| NCT07009925 | Jiangsu Cancer Institute & Hospital | Squamous Cell Lung Cancer | 2025-06 | PHASE2 |
| NCT07208773 | MediLink Therapeutics (Suzhou) Co., Ltd.|Akesobio | Advanced Solid Tumors|Non Small Cell Lung Cancer|Small Cell Lung Cancer | 2025-10-29 | PHASE1|PHASE2 |
| NCT07393555 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8 | 2026-08-07 | PHASE2 |
| NCT07560124 | Akeso | Breast Cancer | 2026-06-06 | PHASE1|PHASE2 |
| NCT07095803 | Sheng Zhang | Multiple Advanced Tumors After PD-1 Therapy Failure | 2025-08-01 | PHASE2 |
| NCT06478043 | Zhejiang Cancer Hospital | Extensive-stage Small-cell Lung Cancer | 2024-09-01 | PHASE2 |
| NCT06790212 | Sun Yat-sen University | Colon Cancer | 2025-04-28 | PHASE2 |
| NCT07226544 | City of Hope Medical Center|National Cancer Institute (NCI) | Localized Clear Cell Renal Cell Carcinoma|Resectable Clear Cell Renal Cell Carcinoma|Stage II Renal Cell Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8 | 2026-06-08 | PHASE2 |
| NCT06953999 | Akeso | Pancreatic Cancer | 2025-06-11 | PHASE3 |
| NCT07472478 | Guangdong Provincial People´s Hospital | Lung Cancer (NSCLC)|KRAS G12C Lung Cancer | 2026-03-15 | PHASE2 |
| NCT07535463 | Memorial Sloan Kettering Cancer Center|Summit Therapeutics | Non-Small Cell Lung Cancer | 2026-04-10 | PHASE1|PHASE2 |
| NCT06877650 | Shanghai JMT-Bio Inc. | Advanced Malignant Tumors | 2025-04-11 | PHASE1|PHASE2 |
| NCT06530251 | Akeso | Hepatocellular Carcinoma | 2024-09-24 | PHASE1|PHASE2 |
| NCT06767527 | Akeso | Triple-Negative Breast Cancer (TNBC) | 2025-02-07 | PHASE3 |
| NCT05951608 | Akeso | Advanced Solid Tumors | 2023-10-16 | PHASE1|PHASE2 |
| NCT06944106 | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 2025-03-28 | PHASE2 |
| NCT04736823 | Akeso | NSCLC | 2021-02-01 | PHASE2 |
| NCT05904379 | Akeso | Advanced Non-small-cell Lung Cancer | 2023-07-13 | PHASE1|PHASE2 |
| NCT07010263 | Akeso | Small Cell Lung Cancer | 2025-06-13 | PHASE3 |
| NCT05840016 | Akeso | Advanced Squamous Non Small Cell Lung Cancer | 2023-08-17 | PHASE3 |
| NCT06938321 | Akeso | Biliary Tract Cancer | 2025-04-30 | PHASE1|PHASE2 |
| NCT07114315 | Akeso | Pancreatic Cancer | 2025-09-19 | PHASE2 |
| NCT07103447 | Shuangyue Liu | Breast Cancer - Female | 2025-09-10 | PHASE2 |
| NCT05846867 | Akeso | Colorectal Cancer | 2023-05-08 | PHASE1|PHASE2 |
| NCT04999605 | Akeso | Ovarian Neoplasms|Recurrent Ovarian Carcinoma|Relapsed Ovarian Cancer|Ovarian Cancer | 2021-06-24 | PHASE1|PHASE2 |
| NCT07021950 | Sun Yat-sen University | Colorectal Cancer|Ivonescimab | 2025-08-10 | PHASE2 |
| NCT05247684 | Akeso | Resectable Non-small Cell Lung Cancer | 2022-02-20 | PHASE2 |
| NCT06951503 | Akeso | Colorectal Adenocarcinoma | 2025-05-27 | PHASE3 |
| NCT05227664 | Akeso | Metastatic Triple-negative Breast Cancer|Locally Advanced Triple-negative Breast Cancer | 2022-03-23 | PHASE2 |
| NCT05116007 | Akeso | SCLC, Extensive Stage | 2021-03-29 | PHASE1 |
| NCT06601335 | Akeso | Head and Neck Squamous Cell Carcinoma | 2024-10-30 | PHASE3 |
| NCT06904300 | Sun Yat-sen University | Gastric (Cardia, Body) Cancer | 2025-08-15 | PHASE2 |
| NCT06472895 | Peking University Cancer Hospital & Institute | Renal Cell Carcinoma | 2024-07-20 | PHASE1|PHASE2 |
| NCT06196814 | Hunan Province Tumor Hospital | Efficacy | 2024-10-01 | PHASE1|PHASE2 |
| NCT04900363 | Akeso | Non-small Cell Lung Cancer | 2021-05-21 | PHASE1|PHASE2 |
| NCT04597541 | Akeso | Solid Tumor, Adult | 2020-10-21 | PHASE1|PHASE2 |
| NCT07357220 | Akeso|Shanghai Virogin Biotech Co., Ltd. | Colorectal Cancer With Hepatic Metastases | 2026-03-02 | PHASE1|PHASE2 |
| NCT06718543 | fan li | Rectal Cancer | 2025-02-10 | PHASE2 |
| NCT06396065 | Summit Therapeutics|Akeso | Non-Squamous Non-small Cell Lung Cancer | 2023-05-04 | PHASE3 |
| NCT06769295 | Sichuan University | Lung Cancer, Non-Small Cell | 2025-02-01 | PHASE2 |
| NCT07385001 | Tang-Du Hospital | Esophageal Squamous Cell Carcinoma|Ivonescimab|Neoadjuvant | 2026-01-28 | PHASE1|PHASE2 |
| NCT06537011 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Neoadjuvant Therapy of Operable Locally Advanced Head and Neck Squamous Cell Carcinoma | 2024-08-01 | PHASE2 |
| NCT07052253 | Akeso|TransThera Sciences (Nanjing), Inc. | Hepatocellular Carcinoma (HCC) | 2025-07-18 | PHASE2 |
| NCT07158840 | Akeso | Non-Small Cell Lung Cancer | 2025-09-05 | PHASE2 |
| NCT04047290 | Akesobio Australia Pty Ltd | Neoplasms Malignant | 2019-09-20 | PHASE1 |
| NCT06809517 | Guangzhou Medical University | Leptomeningeal Metastasis|Intrathecal Drug Delivery | 2025-03-18 | PHASE1|PHASE2 |
| NCT06646055 | Akeso | Metastatic Pancreatic Ductal Adenocarcinoma | 2025-01-21 | PHASE1|PHASE2 |
| NCT05382442 | Akeso|Summit Therapeutics | Metastatic Colorectal Cancer | 2022-06-27 | PHASE2 |
| NCT05432492 | Akeso | Hepatocellular Carcinoma | 2022-08-03 | PHASE2 |
| NCT05229497 | Akeso | Advanced Malignant Tumors | 2022-05-04 | PHASE1|PHASE2 |
| NCT05214482 | Akeso | Advanced Malignant Tumors | 2022-01-22 | PHASE1|PHASE2 |
| NCT05636267 | Akeso | NSCLC | 2023-02-10 | PHASE1|PHASE2 |
| NCT05689853 | Akeso | Solid Tumor, Adult | 2023-04-14 | PHASE1|PHASE2 |
| NCT04870177 | Akeso | Gynecologic Cancer|Cancer Metastatic|Ovarian Neoplasms|Cervical Neoplasm|Endometrial Neoplasms | 2021-04-09 | PHASE2 |
| NCT06402435 | Hubei Cancer Hospital | Breast Cancer | 2024-11-28 | PHASE2 |
| NCT06930573 | The First Affiliated Hospital of Zhengzhou University | HCC | 2024-12-04 | PHASE4 |
| NCT06593548 | Fudan University | CRC|MSS|Metastatic Cancer | 2024-11-01 | PHASE2 |
| NCT06637007 | Shanxi Province Cancer Hospital | Sarcoma,Soft Tissue|Sarcoma|Sarcoma of Bone | 2024-08-01 | PHASE2 |
| NCT06591520 | Akeso | Biliary Tract Cancer | 2024-10-20 | PHASE3 |
| NCT06791148 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Gastric Cancer | 2024-07-10 | PHASE2 |
| NCT06684873 | Sun Yat-sen University | NSCLC|Brain Metastasases | 2024-11-02 | PHASE2 |
| NCT07489703 | Sun Yat-sen University | Non-Small Cell Lung Cancer | 2026-04-30 | PHASE2 |
| NCT05499390 | Akeso | Advanced Non-small-cell Lung Cancer | 2022-11-09 | PHASE3 |
| NCT07340476 | Akeso | Healthy Male Subjects | 2025-12-11 | PHASE1 |
| NCT06560112 | Akeso | Recurrent Ovarian Cancer | 2024-11-12 | PHASE2 |
| NCT06686030 | Akeso | Platinum-sensitive Ovarian Cancer | 2025-02-17 | PHASE2 |